Login
$BHVN
$15.29 +$0.84 (5.81%) Close

Company Executives

$BHVN Management Team

Dr. Vlad Coric

Chairman of the Board

Chief Executive Officer

Age 51
Compensation $10.92M USD
Sex Male

Mr. Matthew Buten

Chief Financial Officer

Age 61
Compensation $5.318M USD
Sex Male

Ms. Kimberly Gentile

Senior Vice President - Clinical Operations

Age 56
Compensation $3.765M USD
Sex Female

Dr. Charles Conway

Chief Scientific Officer

Age 60
Compensation $2.793M USD
Sex Male

Mr. William Jones

Chief Commercial Officer

Migraine and Common Diseases

Age 58
Compensation $4.687M USD
Sex Male

Dr. Elyse Stock

Chief Medical Officer

Age 64
Compensation $3.880M USD
Sex Female

Mr. John Tilton

Chief Commercial Officer

Rare and Orphan Diseases

Age 54
Compensation $1.526M USD
Sex Male
Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
Michael T. Heffernan
61 2022
4 years
Independent None stated enGene Holdings, Inc. (NASDAQ: ENGN) $597,937
Robert J. Hugin
71 2022
4 years
Independent None stated Chubb Limited (NYSE: CB) $552,937
Julia P. Gregory
73 2022
4 years
Independent
Audit Committee · Chair
Nurix Therapeutics, Inc. (NASDAQ: NRIX) $560,937
John W. Childs
84 2022
4 years
Independent None stated None stated $555,937
Gregory H. Bailey, M.D.
70 2022
4 years
Independent None stated Manx Financial Group (LSE: MFX) $555,937
Kishan Mehta
40 2022
4 years
Not stated None stated None stated $535,937

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Mar 13, 2026
Katrina VanTyne
sibling of Ms. Gentile, an executive of the Company
$130,048

Employment as Social Media and Digital Marketing Manager with annual base salary.

With the Company Open in proxy
Katrina VanTyne
sibling of Ms. Gentile, an executive of the Company
$13,005
2025

Annual bonus for services performed in 2025.

With the Company Open in proxy
Katrina VanTyne
Amount not stated
2025

Equity grants of options and RSUs received in 2025, vesting in installments through 2028.

With the Company Open in proxy
Katrina VanTyne
Amount not stated
2026

Option grant received February 27, 2026 in respect of 2025 performance, vesting in installments through 2029.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support